The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Aegerion Pharmaceuticals' lomitapide for treatment of patients with homozygous familial hypercholesterolemia. If approved in Europe, the drug will be marketed under the name Lojuxta. Lomitapide was approved in the U.S. last year with the brand name Juxtapid.

Related Summaries